Biomarkers related to bullous pemphigoid activity and outcome. Issue 12 (27th December 2017)

• Record Type: Journal Article
• Authors: Giusti, Delphine; Le Jan, Sébastien; Gatouillat, Gregory; Bernard, Philippe; Pham, Bach Nga; Antonicelli, Frank
• Other Names: Antonicelli Frank guestEditor.; Ludwig Ralf J. guestEditor.
• Is Part Of: Experimental dermatology. Volume 26:Issue 12(2017)
• Page Start: 1240
• Page End: 1247
• Publication Date: 2017-12-27
• Subjects: autoantibodies -- autoimmunity -- bullous pemphigoid -- cytokines -- inflammation; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/exd.13459
• Languages: English
• ISSNs: 0906-6705

Abstract

Abstract: Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin. Investigation of the BP‐associated pathophysiological processes during the last decades showed that the generation of autoantibodies directed against the hemidesmosome proteins BP180 and BP230, a hallmark of the BP‐associated autoimmune response, leads to the recruitment of inflammatory immune cells at the dermal‐epidermal junction, and subsequently to the release of a large amount of inflammatory molecules involved in blister formation. Analysis in transversal and longitudinal studies of autoantibodies and inflammatory molecules production both at the time of diagnosis and under treatment was mainly performed within the serum but also in the blister fluid. Some autoimmune or inflammatory molecules expression was related to the presence of clinical signs, while others were mere bystanders. In this review, we focused on the autoimmune and inflammatory molecules that have been identified as potential biomarkers of BP development and outcome.